HeyJaredOncology Brothers: Practice-Changing Cancer Discussions
On a mission to disseminate information to the community and bridge the gap between academia and community oncology in this rapidly changing field of hematology & oncology. Drs.
- Indexed episodes, last 90 days
- 22
- Latest publication
- Sep 7, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 5, 2026
Latest episodes
Myelofibrosis Treatment Algorithm Discussion: Dr. Nico Gagelmann (opens the original)
Read excerpt
Welcome to the Oncology Brothers podcast! In this episode, we had the opportunity to dive deep into the treatment algorithm for myelofibrosis with Dr. Nico Gagelmann of Dana-Farber Cancer Institute. Join us as we explored: The critical distinction between primary and secondary myelofibrosis and its implications for treatment The essential workup needed before initiating therapy, including bone marrow biopsy and mutation analysis Anemia management strategies, including the use of erythropoiesis-s
Managing Toxicities of Therapies in Polycythemia Vera (PV) / Essential Thrombocythemia (ET) (opens the original)
Read excerpt
Welcome back to the Oncology Brothers podcast! In this episode, we were joined by the MPN specialists Drs. Brandi Reeves and Naveen Pemmaraju, to discuss the treatment options for polycythemia vera (PV) and essential thrombocythemia (ET). We dived deep into the side effect profiles and management strategies for key treatments, including: Hydroxyurea : Learnt about dosing strategies, monitoring, and the importance of managing acute and chronic side effects such as leg ulcers and skin cancer risks
VERIFY: FDA Approval of Rusfertide in Polycythemia Vera (PV) - Dr. Andrew Kuykendall (opens the original)
Read excerpt
Welcome to the Oncology Brothers podcast! In this episode, we dived into the recent approval of rusfertide for polycythemia vera, based on the findings from the VERIFY study . We were joined by Dr. Andrew Kuykendall , an MPN specialist from the Moffitt Cancer Center, who shared insights on the drug's mechanism of action as a hepcidin mimetic and its clinical implications. Key topics discussed included: The unique challenges of managing polycythemia vera, with balancing of erythrocytosis and iron
Polycythemia vera (PV) and Essential thrombocythemia (ET) Treatment Algorithm: Dr. Aaron Gerds (opens the original)
Read excerpt
Welcome to the Oncology Brothers podcast! In this episode, we are joined by Dr. Aaron Gerds, a hematologist from the Cleveland Clinic, to discuss the current treatment algorithms for myeloproliferative neoplasms (MPNs), specifically focusing on polycythemia vera (PV) and essential thrombocythemia (ET). Join us as we delved into: The diagnostic criteria for PV and ET, including the significance of JAK2 mutations and erythropoietin (EPO) levels The role of bone marrow biopsies in diagnosing and ma
Multiple Myeloma Management - Partners in Practice with Dr. Ajai Chari Team from UCSF (opens the original)
Read excerpt
Welcome to the Oncology Brothers podcast! In this episode of our Partners in Practice series, we dived into the world of multiple myeloma treatment. We had the opportunity to engage with the dedicated team from UCSF, including Dr. Ajai Chari , a myeloma specialist, nurse practitioner Samantha Shenoy, NP , and clinical nurse Jenny Truong, RN . In this insightful discussion, we covered: The current standard of care for newly diagnosed multiple myeloma patients, focusing on quadruple therapy The ro
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.
See coverage about Oncology Brothers: Practice-Changing Cancer Discussions